Your browser is no longer supported. Please, upgrade your browser.
ACRS Aclaris Therapeutics, Inc. weekly Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.47 Insider Own5.50% Shs Outstand30.90M Perf Week0.62%
Market Cap547.86M Forward P/E- EPS next Y-3.21 Insider Trans2.28% Shs Float28.73M Perf Month-1.55%
Income-70.40M PEG- EPS next Q-1.00 Inst Own93.40% Short Float17.44% Perf Quarter-27.34%
Sales1.70M P/S322.27 EPS this Y-11.50% Inst Trans0.25% Short Ratio16.14 Perf Half Y-34.41%
Book/sh7.30 P/B2.43 EPS next Y22.70% ROA-32.30% Target Price47.17 Perf Year-44.99%
Cash/sh6.28 P/C2.83 EPS next 5Y- ROE-34.30% 52W Range16.01 - 32.65 Perf YTD-28.10%
Dividend- P/FCF- EPS past 5Y- ROI-32.10% 52W High-45.70% Beta-
Dividend %- Quick Ratio15.70 Sales past 5Y- Gross Margin28.30% 52W Low10.74% ATR0.83
Employees96 Current Ratio15.70 Sales Q/Q- Oper. Margin- RSI (14)48.74 Volatility3.94% 4.70%
OptionableYes Debt/Eq0.00 EPS Q/Q-63.60% Profit Margin- Rel Volume0.86 Prev Close17.60
ShortableYes LT Debt/Eq0.00 EarningsMar 12 BMO Payout- Avg Volume310.48K Price17.73
Recom1.30 SMA202.34% SMA50-5.42% SMA200-25.00% Volume267,875 Change0.74%
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Apr-18-18 07:35AM  Investor Expectations to Drive Momentum within Casella Waste, Prologis, Flushing Financial, AMERISAFE, Aclaris Therapeutics, and NanoString Technologies Discovering Underlying Factors of Influence GlobeNewswire
Apr-06-18 07:00AM  Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics CNW Group
07:00AM  Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada GlobeNewswire
Apr-03-18 04:05PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-29-18 08:10AM  Analysis: Positioning to Benefit within TopBuild, MarketAxess, Provident Financial Services, SailPoint Technologies, Aclaris Therapeutics, and VOXX International Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-21-18 07:30AM  Blog Exposure - Aclaris Therapeutics Shares Positive Update on Phase-2 Results after a 3-Month Follow-Up of A-101 45% Topical Solution ACCESSWIRE
Mar-20-18 07:00AM  Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine GlobeNewswire
Mar-19-18 08:00AM  Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts GlobeNewswire
Mar-14-18 03:20PM  Aclaris experimental hair loss treatment gets additional patent protection American City Business Journals
Mar-13-18 12:03PM  Aclaris Therapeutics (ACRS) Q4 2017 Earnings Conference Call Transcript Motley Fool
03:16AM  Edited Transcript of ACRS earnings conference call or presentation 12-Mar-18 12:00pm GMT Thomson Reuters StreetEvents
Mar-12-18 07:13AM  Aclaris reports 4Q loss Associated Press -7.19%
07:00AM  Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Aclaris Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire
Mar-09-18 08:00AM  Aclaris Therapeutics Announces Issuance of U.S. Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders GlobeNewswire
Mar-06-18 04:05PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-28-18 08:00AM  Aclaris Therapeutics to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018 GlobeNewswire
Feb-15-18 07:39AM  Could These 2 Biotech Stocks Really Double Your Money? Motley Fool
Feb-08-18 05:44PM  Aclaris Therapeutics to Present Data on ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting GlobeNewswire
Feb-05-18 04:01PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-02-18 08:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire -5.12%
Jan-29-18 08:20AM  Report: Developing Opportunities within The KEYW Holding, Aclaris Therapeutics, Vera Bradley, Stewart Information Services, Eros International, and Smart Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-08-18 11:40AM  Malvern firm's common warts treatment show promise in mid-stage testing American City Business Journals
07:00AM  Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts GlobeNewswire
Jan-04-18 04:01PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-19-17 07:00AM  Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo GlobeNewswire
Dec-18-17 07:20AM  Blog Exposure - FDA Approves Aclaris Therapeutics' ESKATA Topical Solution for Treatment of Common Skin Growths ACCESSWIRE
Dec-15-17 09:21AM  Stocks to Watch: CSX, Hess, Adobe, Costco, Aclaris Therapeutics The Wall Street Journal
08:19AM  Aclaris's drug to treat common skin growth gets FDA nod Reuters
07:00AM  Aclaris Therapeutics Receives FDA Approval for ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs) GlobeNewswire
Dec-13-17 02:21PM  Aclaris Therapeutics, Inc. Value Analysis (NASDAQ:ACRS) : December 13, 2017 Capital Cube
Dec-12-17 07:22AM  Aclaris Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACRS-US : December 12, 2017 Capital Cube
Dec-07-17 06:00AM  Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences PR Newswire
Nov-30-17 08:18AM  5 Biotech and Pharma Stocks with FDA Catalysts this December Zacks
Nov-21-17 08:00AM  Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor GlobeNewswire
Nov-09-17 04:05PM  Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly GlobeNewswire
04:34AM  Edited Transcript of ACRS earnings conference call or presentation 7-Nov-17 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 07:25AM  Aclaris reports 3Q loss Associated Press -8.45%
07:00AM  Aclaris Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-03-17 08:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
Nov-02-17 08:00AM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-31-17 08:00AM  Aclaris Therapeutics to Announce Third Quarter 2017 Financial Results on November 7, 2017 GlobeNewswire
Oct-24-17 08:00AM  Aclaris Therapeutics Announces the Allowance of a U.S. Patent Application and Issuance of a Japanese Patent Covering Tofacitinib for Treating Hair Loss Disorders GlobeNewswire
Oct-06-17 07:46PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-20-17 08:00AM  Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York GlobeNewswire
Sep-19-17 08:00AM  Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis GlobeNewswire
Sep-07-17 04:01PM  Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-05-17 08:00AM  Aclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders GlobeNewswire
Aug-17-17 08:00AM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire -5.00%
Aug-12-17 08:16AM  Edited Transcript of ACRS earnings conference call or presentation 8-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 07:40PM  Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire -14.65%
Aug-09-17 04:01PM  Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire
08:00AM  Aclaris Announces Appointment of Andrew Schiff to Board of Directors GlobeNewswire
Aug-08-17 11:54PM  Aclaris reports 2Q loss Associated Press
06:06PM  [$$] Aclaris Therapeutics Buys Confluence Life Sciences in $100 Million Deal The Wall Street Journal
07:01AM  Aclaris Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
07:00AM  Aclaris Therapeutics Acquires Confluence Life Sciences, Inc. GlobeNewswire
05:50AM  Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:00AM  Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis GlobeNewswire
Aug-02-17 08:00AM  Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata GlobeNewswire
Aug-01-17 08:56AM  UPDATE - Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
08:00AM  Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jun-29-17 08:00AM  Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts GlobeNewswire
Jun-13-17 08:00AM  Aclaris Therapeutics Announces Issuance of New U.S. Patent For A-101 Topical Solutions GlobeNewswire
May-09-17 06:08PM  Aclaris reports 1Q loss Associated Press
05:48PM  Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
04:05PM  FDA Accepts Aclaris Therapeutics New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition GlobeNewswire
04:01PM  Aclaris Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
01:15PM  Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call Accesswire
May-05-17 08:00AM  Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis GlobeNewswire
May-01-17 04:08PM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
04:08PM  Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
Apr-26-17 07:00AM  Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution GlobeNewswire
Apr-24-17 08:00AM  Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting GlobeNewswire
Apr-04-17 08:00AM  Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Respectively, for Hair Loss Disorders GlobeNewswire
08:00AM  Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Respectively, for Hair Loss Disorders
Mar-18-17 01:04PM  ACLARIS THERAPEUTICS, INC. Financials
Mar-15-17 07:25PM  Edited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT Thomson Reuters StreetEvents
07:25PM  Edited Transcript of ACRS earnings conference call or presentation 15-Mar-17 12:00pm GMT
08:00AM  Aclaris Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:23AM  Aclaris reports 4Q loss Associated Press
07:23AM  Aclaris reports 4Q loss
07:16AM  ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q4 2016 Aclaris Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update GlobeNewswire
Mar-01-17 09:22AM  Humana (HUM) Includes Methodist Healthcare in its Network
Feb-27-17 08:00AM  Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis a Common Skin Condition GlobeNewswire
Feb-24-17 08:45AM  Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5% Zacks
08:45AM  Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5%
Feb-23-17 08:00AM  Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 GlobeNewswire +8.57%
Feb-06-17 04:08PM  Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire
02:01PM  Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO TheStreet.com
02:01PM  Skin Lesion Drug Only Scratches the Surface, Says Aclaris CEO
Jan-26-17 08:31AM  ACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
08:00AM  Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors GlobeNewswire
Jan-03-17 08:44AM  Why Aclaris Therapeutics (ACRS) Stock Might be a Great Pick
08:00AM  Aclaris to Present at 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-09-16 06:00AM  Aclaris Therapeutics Inc (ACRS) Hedge Funds Are Snapping Up at Insider Monkey
Dec-07-16 08:00AM  Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis GlobeNewswire
Dec-02-16 11:00AM  Why Aclaris (ACRS) Could Be Positioned for a Surge
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ruffo FrankChief Financial OfficerApr 06Buy16.591,25020,738155,615Apr 09 04:51 PM
Tullman Stephen A.DirectorApr 06Buy16.5426,700441,618157,507Apr 09 04:50 PM
Walker NealPresident and CEOApr 05Buy16.7510,000167,500897,184Apr 09 08:38 AM
Molineaux Christopher P.DirectorMar 20Option Exercise0.552,3771,3059,982Mar 22 04:35 PM
SCHIFF ANDREW NDirectorAug 16Buy23.02108,6012,499,995634,455Aug 16 04:45 PM